Company Update: SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM | Learn More
Logo yposkesi
waves image

Meet our team at the Phacilitate Advanced Therapies Conference: Sept. 6-7, 2023 in Lisbon, Portugal.

The event

The Phacilitate Advanced Therapies Europe conference will take place September 6-7 2023 at the Estoril Congress Center in Lisbon, Portugal.

Learn more about the event

Our team

Meet our team during the event: 

Stop by our booth #24 to meet our team during the Phacilitate Advanced Therapies Europe conference and learn more about our extended services to bring your cell and gene therapies to life… From process development up to commercial launch, Yposkesi is the full-service CDMO of choice, working by your side, to meet your timelines and budget.

Learn more about our newly re-launched lentivirus manufacturing platform: LentiSure!

At the beginning of April 2023, Yposkesi launched its new Lentiviral Vector Manufacturing Platform, LentiSure.

LentiSure is providing the premium quality grade lentiviral vectors you need to assure your clinical development and commercial cell and gene therapy pipeline. LentiSure’s robust, scalable, and plug & play-optimized processes enable you to accelerate the time to market of your cell and gene therapies and facilitate better patient outcomes. You obtain a safe and effective product through LentiSure’s high productivity and established analytical methods. LentiSure is the choice for high titers, transduction efficiency, reliability, and accessing scalable production processes with optimized purification techniques.


Created by Yerokhoff Kostyiantine